3:03 PM
 | 
Nov 15, 2017
 |  BC Extra  |  Clinical News

Acorda falls on tozadenant safety concerns

Acorda Therapeutics Inc. (NASDAQ:ACOR) lost $11.20 (40%) to $17 on Wednesday after disclosing cases of agranulocytosis that were possibly related to treatment with Parkinson's disease candidate tozadenant (SYN115) and in some cases associated with sepsis and death.

Among about 890 patients who received the selective adenosine A2A receptor (ADORA2A) antagonist across the company's Phase IIb and Phase III trials, Acorda reported seven cases of...

Read the full 298 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >